Abstract. A proof-of-concept study was performed to demonstrate that carboxyl group footprinting, a relatively simple, bench-top method, has utility for first-pass analysis to determine epitope regions of therapeutic mAb:antigen complexes. The binding interface of vascular endothelial growth factor (VEGF) and the Fab portion of a neutralizing antibody (Fab-1) was analyzed using carboxyl group footprinting with glycine ethyl ester (GEE) labeling. Tryptic peptides involved in the binding interface between VEGF and Fab-1 were identified by determining the specific GEE-labeled residues that exhibited a reduction in the rate of labeling after complex formation. A significant reduction in the rate of GEE labeling was observed for E93 in the VEGF tryptic peptide V5, and D28 and E57 in the Fab-1 tryptic peptides HC2 and HC4, respectively. Results from the carboxyl group footprinting were compared with the binding interface identified from a previously characterized crystal structure (PDB: 1BJ1). All of these residues are located at the Fab-1:VEGF interface according to the crystal structure, demonstrating the potential utility of carboxyl group footprinting with GEE labeling for mapping epitopes.
Introduction E pitope mapping of monoclonal therapeutic antibodies (mAbs) and their specific targets (antigens) is important for antibody design and intellectual property (IP). The Bgold standard^for epitope mapping is X-ray crystallography, which provides high-resolution information on binding interactions, although the static information gathered from the crystalline state may have limited biological relevance [1, 2] . Crystallizing large molecular complexes such as antibody:antigen complexes can also be challenging [3, 4] .
Liquid chromatography mass spectrometry (LCMS)-based footprinting is a Bbottom-up^approach to structural characterization in which labeled proteins are enzymatically cleaved into peptides before LCMS analysis. To infer the structure of the protein, information on the solvent accessibility of the peptides must be encoded into the peptides prior to digests by means of either reversible (e.g., hydrogen/deuterium exchange, H/DX) [5] [6] [7] , or irreversible (e.g., hydroxyl radicals) chemical probes [8] [9] [10] [11] . Quantitation of the labeled peptides yields insight into the solvent accessibility of the peptides and thus their associated protein regions. H/DX is the industry leading technology for footprinting-based epitope mapping, with other methods such as hydroxyl radical labeling (oxidative footprinting) showing promise [12] [13] [14] .
In this study, we perform carboxyl group footprinting to incorporate GEE onto the solvent-accessible carboxylic acid moieties (aspartate (D), glutamate (E), and C-terminus) using the coupling agent, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) [15] . This method has advantages compared with other LCMS-based footprinting methods, such as H/DX and oxidative footprinting, including: advanced instrumentation is not required; analysis is simplified because of the limited number of potential peptides labeled by GEE; and efficient labeling is possible in pharmaceutically relevant formulations, which may otherwise interfere with the other types of probes (e.g., stabilizing detergents, antioxidants, pH) [16, 17] . This method was recently employed to study the structure/function relationship of a membrane-bound receptor tyrosine kinase heterodimer complex, in which results from other footprinting methods proved difficult to intpret [18] . Although this method is relatively simple compared with other HOS methods, one disadvantage is that a solventaccessibile carboxylic acid group must be located at the region of interest for structural information to be obtained.
The current work was performed to determine if carboxyl group footprinting could successfully map the epitope binding interface of the previously crystallized Fab-1:VEGF complex [19] . We performed the labeling experiments on the unbound proteins and bound Fab-1:VEGF complex, and generated dose-response plots (DR-plots) to calculate the rate constants for all tryptic peptides containing labeled sites [20] . These rate constants putatively reflect the average rate of labeling for all the labeled sites in a given peptide. We then calculated normalized rate constant ratios (bound/unbound states) for GEE-labeled peptides to identify peptides with significant reduction in GEE incorporation upon binding. Reduction in GEE incorporation reflects a decrease in solvent accessibility, thus signifying the peptides that may be located at the binding interface. Labeling limited to carboxylic acid moieties produces relatively less complex MS and MS 2 data sets compared with other footprinting techniques, allowing for facile extraction of further structural information at individual amino acid residue levels. For example, in the case for peptides containing only one labeled site, the apparent rate constant reflects the rate of labeling for that particular residue only. Consequently, further examination of the mass spectra of peptides with significant reduction in labeling upon binding may reveal specfic amino acid residues that are likely involved in the binding interface.
Fab-1 contains nine total tryptic peptides in both the heavy chain (HC) and light chain (LC) with potental labeling sites (~70% sequence coverage). We observed no tryptic peptides in the LC with significant changes in GEE labeling; however, we identified two tryptic peptides in the HC that exhibited significant reduction in GEE incorporation when bound in the Fab-1:VEGF complex, inferring that these peptides are at the binding interface. Indeed, both of the tryptic peptides contain complementary determining regions (CDRs), and have at least one D or E residue within their respective CDR sequence. We identified D28 (CDR1) and E57 (CDR2) have significant reduction in GEE incorporation, suggesting these are at the binding interface. We also identified a tryptic peptide in VEGF with a rate of incorporation so slow in the Fab-1:VEGF complex that a DR-plot could not be generated, indicating a significant reduction in solvent accessibility. This tryptic peptide contains residue E93, previously shown to be critical for antigen binding [19] . Mapping the identified residues onto the crystal structure demonstrates that all three of these residues and their associated tryptic peptides are in fact located at the Fab-1:VEGF interface [19] . Thus, these results demostrate that carboxyl group footprinting may provide a simple strategy for investigating the binding interfaces of therapeutic proteins.
Experimental

Materials and Reagents
VEGF and Fab-1 were produced in E. coli. cells, purified, and formulated for bulk drug substance. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Fab-1:VEGF complex was prepared and purified as descibed in the Supplemental Information.
Data Analysis
DR-plots were generated to determine the rate constants of GEE incorporation for all peptides in both the unbound (free protein) and bound (Fab-1:VEGF complex) states using ProtMapMS (Case Western Reserve University, Cleveland, OH, USA). Rate constant ratios (rate constant of bound/rate constant of unbound state) were then determined for every labeled peptide. We designated significant differences in rates of labeling to be 50% or greater change from the value of 1 (e.g., ≤0.5 or ≥1.5). Further detail is described in the Supplemental Information.
Results and Discussion
Carboxyl Group Footprinting Rate Constant Determination
We performed carboxyl group footprinting on unbound Fab-1 and VEGF proteins and on the Fab-1:VEGF complex to determine the rate constants for incorporation of GEE on their peptides after tryptic digestion. The full total ion chromatograms (TIC) and sequence coverage are shown in Figure S2 and Table S3 , respectively. We then used ProtMapMS to generate the DR-plots and the rate constants for labeled peptides ( Figure S3 ). Linearity verification of the DR-plots ensures the labeling procedure is not disrupting the local microenvironment for a given peptide [21] [22] [23] ; therefore, we only included data points prior to any deviation in linearity (i.e., the initial rate of incorporation) to calculate the rate constants for each peptide from the bound and unbound states ( Figure S3 , Tables S4 and  S5 ). The normalized rate constant ratios for the bound/unbound states were then calculated to determine significant changes in GEE incorporation and, therefore, changes in solvent accessibility for a given peptide (see Data Analysis).
Mapping of the Fab-1:VEGF Interface
For this study, we only have focused on the six tryptic peptides containing the known CDR sequences for Fab-1 (three in LC, three in HC) expected to contribute to the binding interaction with VEGF. Only two of the three LC CDR-containing peptides have GEE incorporation sites (tryptic peptides LC2 and LC5), and only LC2 has a potential GEE labeling site within the CDR sequence. Tryptic peptide LC3(CDR2) does not contain GEE incorporation sites within the CDR sequence, and is not expected to show a change in solvent accessibility.
We did not observe any significant change in solvent accessibility for either LC2 and LC5 in the bound state (Table 1, Figure S4 ). These results are consistent with the previous crystal structure analysis describing that LC2(CDR1) is not in contact with VEGF. All three of the HC CDR-containing tryptic peptides (HC2, HC4, HC10) have potential GEE labeling sites within their CDR sequences. We observed significant decreases in solvent accessibilty for HC2(CDR1) and HC4(CDR2) in the bound state, consistent with their involvement in the binding interface (Table 1, Figure S3 and S4). HC10(CDR3) displayed no change in solvent accessibility, indicating that this peptide is not involved in binding [19] . Interestingly, HC9 does not contain a CDR sequence, yet exhibits siginificant decrease in GEE incorporation. This likely reflects a conformational change subsequent to antigen binding.
The VEGF protein contains 11 total tryptic peptides with the potential for GEE incorporation: however, only five of these peptides are found in the crystal structure of the Fab-1:VEGF complex (PDB:1BJ1) and are, therefore, the focus of this study (V2-V6). Of these five peptides, only peptide V5 exhibited a significant decrease in GEE incorporation in the bound state (Table 1, Figure S3 ). In fact, the rate of GEE incorporation for V5 was so low that we could not obtain a DR-plot from the Fab-1:VEGF complex, indicating this peptide is tightly bound in the complex (Figures S3 and S4) . Indeed, tryptic peptide V5 contains many of the critical residues involved in Fab-1:VEGF binding [19] .
Residue-level details were determined to further resolve the binding interface. Peptides HC2 in Fab-1 and V5 in VEGF contain only a single D or E residue, indicating that GEE incorporation is located only on residues D28 and E93, respectively. Therefore, both residues are implicated as important for binding. HC4 contains three sites for potential GEE labeling (Table 1) , but only E57 and D63 are in the CDR sequence. Our MS 2 data demonstrates E46 is not labeled in either state and, therefore, is presumed not to be involved in binding ( Figures S5 and S6 ). In addition, we observe that the overall change in solvent accessibility for HC4 is due to a change in the labeling at E57 and not D63 (based on the area under the curve), indicating that only E57 is located at the binding interface. D111 in tryptic peptide HC10(CDR3) is not labeled in either state and, therefore, presumed to not be involved in binding. Mapping all of the amino acid residue-level 
Conclusion
Carboxyl group footprinting is rapidly gaining attention as a useful strategy for structural determinations. Here we performed a proof-of-concept study to determine the utility of this method for examining the epitope binding region of an antibody:antigen complex. We demonstrate that the peptides with reduced GEE incorporation upon binding are consistent with regions previously identified to be located at the binding interface of the Fab-1:VEGF complex. The method also allowed for the putative identification of specific amino acids involved in the binding interface. This technique may have advantages compared with H/DX and oxidative footprinting in the pharmaceutical and biotechnology sectors as a relatively simple, bench-top approach to epitope mapping and determining protein-protein interactions.
